Targeting hyperinsulinaemia in castrate resistant prostate cancer

Approximately 25% of men diagnosed with prostate cancer fail primary therapy and commence androgen deprivation therapy. This induces the ‘metabolic syndrome’ and high serum insulin levels, in turn associated with poor prognosis. This project investigates the biological effects of two drugs, clinically used to treat type 2 diabetes, metformin and thiazolidinediones, on pathways activated by insulin in androgen-deprived prostate cancer cells. These findings will provide rationale to target insulin pathways in advanced prostate cancer.

Two major pathways were nominated for investigation in this project:

  • lipogenesis and steroid biosynthesis;
  • EMT and cytotoxic resistance.


Jennifer Gunter APCRC-Q, IHBI, QUT, TRI

Associate Investigators

Colleen Nelson APCRC-Q, IHBI, QUT, TRI
Brett Hollier APCRC-Q, IHBI, QUT, TRI
Michael Pollak McGill University, Canada
Ladan Fazli Vancouver Prostate Centre


2013 - 2015


Cure Cancer Australia Foundation and Prostate Cancer Foundation of Australia $351 108

Upcoming Events

Jul 19, 2020 - Jul 21, 2020 ANZUP 2020 Annual Scientific Meeting
Adelaide Convention Centre, South Australia
Aug 18, 2020 - Aug 21, 2020 PA Hospital Health Symposium
Russell Strong Auditorium, Princess Alexandra Hospital, 199 Ipswich Rd, Woolloongabba
Aug 21, 2020 - Aug 23, 2020 21st Asia-Pacific Prostate Cancer Conference
Melbourne Convention and Exhibition Centre, Victoria
Sep 29, 2020 - Oct 02, 2020 ComBio 2020
Melbourne Convention and Exhibition Centre, Victoria
Nov 11, 2020 - Nov 13, 2020 COSA Annual Scientific Meeting
Brisbane Convention and Exhibition Centre, Queensland